

Conversations with the Academy

a Value-Added Programs Initiative

Dear Honorio,

As you've heard earlier, we are excited to launch a new learning initiative, “Conversations with the Academy.” It is geared to offer new options in continuing professional development and will include activities such as webinars, panel discussions, and expert interviews. The aim of these activities will be to provide rich learning and networking opportunities that interest our participants and engage them.

Registration for the forthcoming sessions is still open! Please see below for registration details and information on the webinars!

We would also be very appreciative of your feedback on these initial activities. Your wisdom and experience are incredibly valuable to us as we determine VAP (Value Added Program) speakers and topics, work to ensure the continued success of IFAPP Academy, and promote excellence in medicines development.

We hope to see you there as we continue this journey of continuous learning together.

Looking forward to your participation, we remain,

Yours sincerely,

Honorio Silva
President, IFAPP Academy

Jacob Coots
Program Manager, IFAPP Academy

Webinars

1.) Antimicrobial Resistance and the Pharmaceutical Industry

with Pol Vandenbroucke

Date: September 17th, 2020, 9 am EST

Speaker: Pol Vandenbroucke, MD, MSc, FPFM
Chief Medical Officer, Pfizer Hospital Division

Hosts: Honorio Silva, MD and Bruce Altevogt, PhD

Background: Antimicrobial Resistance or AMR – when bacteria evolve to resist the effects of antibiotics – is making it increasingly difficult to treat common infections like pneumonia, tuberculosis, and salmonellosis and is responsible for the death of more than 700,000 people each year worldwide. AMR does not consistently maintain the public's attention, yet it is an urgent and growing problem that could roll back a century of health and development progress. While the World Health Organization (WHO) has recognized AMR as one of the *leading* global public health challenges, the fight against AMR is urgent and must be multi-faceted, including surveillance to understand global and local resistance patterns, antimicrobial stewardship for the preservation of current antibiotics through appropriate use, development of new antimicrobials and vaccines, adequate policies to support development and access and public awareness to change daily human behavior to improve handwashing and take antibiotics as directed.

Expected Learning Outcomes:

- Understand the problem of AMR, its causes and its potential impact
- Learning about the different tools to combat the rising rate of AMR
- Understand the role professionals involved in Medical Affairs and Medical Development may play in this fight

[Details and Registration - Click Here](#)

**2.) Applying Established Principles of Vaccine Clinical Development
in a Pandemic**

with Stephen Lockhart

Date: October 1st 2020, 8 am EST

Speaker: Stephen Lockhart

Vice President and Head of Europe and Asia-Pacific
Vaccine Clinical Research and Development at Pfizer.

Hosts: Seema Haider, PhD (USA) and Sandor Kerpel-Fronius, MD, PhD

Background: Active immunization plays a major role in preventing infectious diseases. Although there are many different types of vaccines, some common themes can be perceived in how new vaccines are taken through clinical development. These include the relevance and limitations of immune response markers, systematic approaches to rapid assessment

of safety and reactogenicity, and efficient design of efficacy studies with clinically relevant case definitions. In a pandemic situation, new vaccines are urgently required but the same principles apply. In this webinar, I will illustrate these points with both already approved vaccines and how they are being applied by developers of COVID-19 vaccines.

Expected Learning Outcomes:

- Understanding the types of immune marker, and their relevance and limitations
- Awareness of methods for systematic assessment of vaccine safety and tolerance
- Appreciating the difference between useful defining cases in efficacy studies and diagnostics for clinical practice

[Details and Registration - Click Here](#)